Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TELK -- Telik, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (382)	8/29/2003 6:23:20 PM
From: Miljenko Zuanic	Respond to of 887

I also do not have anything new on L7. I visited TELK patent on 19781, but can not say is there something of value that can be part of the preclinical stage. Problem with L7 and similar molecules is that it can activate other Trk-X family and you have a problem (big problem). Is TELK compound(s) specific for Trk IR-beta (and sufficiently potent) I can not say from abstract (WE) and patent data. If they have success in PI (safety), than we can start looking deep on this candidate. Miljenko